Cancer stem-neuroendocrine cells in an atypical carcinoid case report
Open Access
- 1 December 2019
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 8 (6) , 1157-1162
Abstract
Lung neuroendocrine cells tumor (NET) classification and diagnosis, particularly for typical and atypical carcinoids, are complicated by a variable natural history and nonspecific symptoms. Mechanisms for the development and progression of well-differentiated lung NETs are still unclear. An accurate and timely diagnosis can ensure the implementation of appropriate treatment and impact on prognosis. One of the main unclear point is the definition of these cells’ composition. In fact, it is known that carcinoids are mainly constituted by neuroendocrine cells. Aim of our report is to show for the first time the presence of a high percentage of cancer stem cells (CSCs) in an atypical carcinoid. The ALDEFLUOR assay was used to identify and sort ALDHhigh and ALDHlow human lung cancer cells following tissue digestion. SOX2 was additionally determined by immunohistochemistry. All specimens contained the 53.10% of ALDHhigh cells among all viable lung cancer cells, which indicates that more than half of the entire tumor cell population was composed by CSCs. As expected also in immunohistochemistry, about a half of the nuclei of the cells were positive for SOX2. We strongly support the hypothesis of the presence of cancer stem-neuroendocrine cells (CSCs-NETs) as subpopulation in these types of tumors.Keywords
This publication has 14 references indexed in Scilit:
- ALDH as a Stem Cell Marker in Solid TumorsCurrent Stem Cell Research & Therapy, 2019
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposalLaboratory Investigation, 2018
- Advanced Typical and Atypical Carcinoid Tumours of the Lung: Management RecommendationsCurrent Oncology, 2018
- Nothing But NET: A Review of Neuroendocrine Tumors and CarcinomasNeoplasia, 2017
- Classification of pulmonary neuroendocrine tumors: new insightsTranslational Lung Cancer Research, 2017
- Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated DiseaseJournal of Thoracic Oncology, 2017
- Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targetsAnnals of Translational Medicine, 2016
- Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cellsOncotarget, 2016
- Classification of lung neuroendocrine tumors: lights and shadowsEndocrine, 2015
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008